HER2-Negative Breast Cancer
2 competing products in clinical development for HER2-Negative Breast Cancer.
Pipeline by Phase
Phase 21
Phase 31
All Products (2)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| E7389 (Eribulin Mesylate) + Vinorelbine injection | Eisai | Phase 3 | Completed | 40 |
| Eribulin + Cyclophosphamide + Docetaxel | Eisai | Phase 2 | Completed | 35 |